Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG4050 in Advanced Head and Neck Cancer
2023-508561-33-00Phase 2Authorised
- Sponsor
- Transgene SA
- Start
- Dec 2019
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 4
01
Overview
Phase 2 trial of TG4050 in head and neck squamous cell carcinoma (HNSCC), sponsored by Transgene SA. Planned start Dec 2019; status: authorised.
02
Drugs
TG4050
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2023-508561-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508561-33-00.